Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy

Click to increase image sizeClick to decrease image size

Acknowledgements

We are grateful to the dedicated physicians and nurses at San Francisco General Hospital. We are particularly grateful to Judith Luce, MD and Donald Abrams, MD, Division of Hematology/Oncology, San Francisco General Hospital.

Designed research: N.K.G., C.C.W. and J.L.R. Performed research and collected data: N.K.G., C.C.W., G.N.M., J.-P.J.Y. and J.L.R. Analyzed and interpreted the data: N.K.G., C.C.W., G.N.M., J.-P.J.Y. and J.L.R. Wrote/reviewed and approved the article: N.K.G., C.C.W., G.N.M., J.-P.J.Y. and J.L.R.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2017.1312374.

Additional information

Funding

Research funding for this work was from Celgene and Genentech (J.L.R.). This work was supported by the NIH R01CA139-83-01A1, and by the Leukemia and Lymphoma Society (J.L.R.).